LQDA Liquidia Corporation

Stock Market Today: The Dow Jones index rises Wednesday on surprise inflation data. Micron earnings are due after the close.

A district judge ruled Wednesday that Liquidia infringed on United Therapeutics' patents with its drug, Yutrepia. The stocks diverged.

Investing.com -- Liquidia Corp shares fell Wednesday after a U.S. District Court in Delaware ruled the company infringed two patent claims held by United Therapeutics Corp. United Therapeutics shares rose more than 13%.

Liquidia's Yutrepia posts rapid sales growth, but intensifying competition from established therapies and emerging drugs could test its momentum.

Liquidia's Yutrepia is gaining traction, but patent litigation, competition, rising costs and heavy product dependence cloud LQDA's outlook.

Liquidia's Yutrepia wins FDA Fast Track status for SSc-related Raynaud's, opening a potential new growth avenue for the lead drug.

Liquidia Corporation recently reported that the U.S. Food and Drug Administration granted Fast Track designation to YUTREPIA (treprostinil) inhalation powder for treating Raynaud's phenomenon associated with systemic sclerosis, and the company expects to begin its Phase 2a RE-WARM dose-finding study in October 2026. This designation highlights a potential new use for an existing pulmonary arterial hypertension therapy in an area where no approved U.S. treatments currently exist, underscoring...

The U.S. Food and Drug Administration has granted Fast Track designation to Liquidia (LQDA) therapy YUTREPIA for Raynaud's phenomenon in systemic sclerosis, drawing investor attention to the stock and its rare disease pipeline. Liquidia’s latest Fast Track news lands after a sharp pullback, with the share price down about 22% over the past month and slightly weaker over the last week, even though the year to date share price return is 118.57% and the 1 year total shareholder return is...

Liquidia stock has delivered very strong long term gains over the past five years, yet current valuation checks present a more cautious picture that investors need to weigh carefully. After such a large move in the share price, the key issue is whether the recent performance and expectations around its pipeline are already fully reflected in what the market is paying today. Over the past five years, Liquidia has returned about 24x. This places a lot of weight on the company continuing to...

Summers Value Partners, a boutique investment firm, noted in its Q2 2026 investor update that The Summers Value Fund delivered strong results in the quarter, returning 41.7% net, outperforming the Russell 2000 Index ETF (IWM), which returned 21.4%, and the Russell 2000 Value Index ETF (IWN), which returned 17.1%. The letter can be downloaded here. The Fund experienced […]

Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies could challenge its momentum.

Investors need to pay close attention to LQDA stock based on the movements in the options market lately.

Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.

LQDA's Yutrepia is driving rapid growth, but intensifying PAH competition could test its ability to sustain momentum.

Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.

YUTREPIA sales hit $170.4 million with 5,000+ patients started on therapy.

Liquidia's Yutrepia is fueling rapid growth, but patent litigation, competition and heavy product dependence weigh on its outlook.

Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating progress from the first quarter. Key changes to the portfolio will include lower concentration and increased investments with near-term catalysts, […]

It needed to post a blowout quarter instead of the good one it delivered.

Liquidia stock has delivered an extremely strong run over the past few years, yet the valuation checks now suggest investors are dealing with a mixed picture rather than a clear bargain or clear overvaluation. After such a sharp move, the recent pullback raises the question of how much of the good news is already reflected in the current price. Liquidia has returned about 28.7x over the last 5 years, which puts recent pricing under closer scrutiny for anyone considering fresh...

Yutrepia sales fuel Liquidia's Q2 growth as revenues surge and profitability rises, while the company targets more than $1 billion in 2027 revenues.

Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.

Liquidia targets more than $1 billion in 2027 net revenues as YUTREPIA gains share and funds a broader inhaled-treprostinil pipeline.

Liquidia Corp (LQDA) posts $170.4 million in quarterly sales and projects over $1 billion in 2027 revenue amid pipeline advancements.

Moby summary of Liquidia Corporation's Q2 2026 earnings call

Liquidia topped Wall Street's second-quarter expectations Wednesday as sales of its lung disease treatment, Yutrepia, grew by double digits.

Alkermes gains 26.5% in three months as strong proprietary product sales and pipeline progress fuel momentum into the rest of 2026.

Liquidia (NASDAQ:LQDA) reported second-quarter 2026 results marked by continued growth for its inhaled treprostinil product YUTREPIA, increased profitability and expanding investment in its clinical pipeline. Chief Executive Officer Roger Jeffs said the company had received approximately 5,900 uniq

Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.

Net product sales for the second quarter surged to $170.4 million from $6.5 million last year, due to higher Yutrepia sales volumes.

Belite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in February 2027 after positive phase III data.

Liquidia Corporation (LQDA) delivered earnings and revenue surprises of +5.71% and +3.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Liquidia Corporation (NASDAQ:LQDA) shares fell 4. 58% in premarket trading on Wednesday after the biopharmaceutical company reported second-quarter earnings below Wall Street expectations, despite revenue coming in slightly ahead of forecasts.

LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of +15.70% and +148.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

RCKT records earnings growth in the second quarter. Kresladi launch preparations advance and RP-A501 safety findings support its next development steps.

AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.

Kodiak launches a global phase III study of KSI-501 in DME, testing its dual IL-6 and VEGF approach for durable disease control.

ANI Pharmaceuticals tops Q2 earnings and sales estimates, but shares fall as the company cuts its 2026 Cortrophin Gel revenue outlook.

Outlook Therapeutics rallies 311.8% in three months as Lytenava's FDA approval boosts optimism ahead of its planned U.S. launch by year-end.

Liquidia, PBF Energy and Forum Energy Technologies pair low beta with positive momentum and growth drivers amid market volatility.

Why Liquidia’s latest profitability milestone matters Liquidia (LQDA) recently reported its third consecutive profitable quarter, supported by real world demand for its FDA approved pulmonary hypertension therapy YUTREPIA and an expanded US$100,000,000 financing agreement with HealthCare Royalty. See our latest analysis for Liquidia. Liquidia’s recent news has arrived alongside strong share price momentum, with a 90 day share price return of 113.29% and a year to date share price return of...

IMCR incurs wider-than-expected Q2 loss. However, revenues beat as sole drug Kimmtrak sales rise 18.3% year over year on higher U.S. and international sales.

OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.

BioMarin stock rises on Q2 sales beat and raises 2026 outlook, highlighting strong Voxzogo growth, Amicus additions and momentum in key therapies.

Management has just raised the peak-sales estimate, and a large slice of it belongs to a drug still running Phase III trials.

Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.

Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.

INSM tops Q2 revenue and earnings estimates as strong Brinsupri uptake drives a 34% stock jump and prompts sharply higher 2026 sales guidance.

Xenon posts a narrower-than-expected Q2 loss as azetukalner advances toward a planned FDA filing, while its cash runway is expected to support operations into 2029.

Viatris tops Q2 earnings and revenue estimates as Greater China sales surge 21%, helping lift results and prompting a higher 2026 financial outlook.